The link between HS and obesity is well established; most patients with HS are overweight or obese, and many suffer from insulin resistance. Semaglutide is a glucagon-like peptide (GLP) 1 receptor agonist that has shown to improve insulin resistance, suppress appetite, and lead to weight loss in overweight and obese patients. Moreover, it has anti-inflammatory effects. This was the rationale for Dr Daniel Lyons (St Vincent’s University Hospital, Ireland) and colleagues to assess the agent in an HS population [1].
The retrospective analysis was conducted between June 2020 and March 2023 and evaluated 30 patients with obesity and varying stages of HS. Participants, primarily women with an average age of 42, were treated with a weekly dose of 0.8 mg semaglutide over an average period of 8.2 months. Most participants were Hurley stage II (n=15), followed by stage III (n=11), and stage I (n=4). All participants received concomitant HS treatment; 10 were on treatment combinations. Several outcomes were assessed, including body mass index (BMI), flare frequency, and the Dermatology Life Quality Index (DLQI).
Semaglutide reduced the frequency of HS flare-ups, from once every 8.5 weeks to once every 12 weeks, and significantly improved quality-of-life. Notably, one-third of participants achieved a clinically meaningful reduction in their DLQI scores (corresponding to a DLQI reduction of four points or more). Additionally, participants experienced substantial weight loss, with the average BMI decreasing from 43.1 to 41.5 and weight dropping by an average of 6 kg. A third of participants lost more than 10kg during the treatment period.
Therapy with semaglutide also improved glycaemic control: HbA1c levels decreased from 39.3 to 36.6 mmol/mol. Moreover, the agent showed to have anti-inflammatory effects, as C-reactive protein (CRP) levels fell from 7.8 to 6.9mg/L.
“Semaglutide offers significant benefits for managing HS, particularly through weight loss and flare reduction, and improving patients’ quality-of-life,” commented Dr Lyons. These results should be assessed in larger, prospective trials to decide whether semaglutide should be integrated into HS treatment regimens.
- Lyons D, et al. Semaglutide for weight loss in obese patients as an adjunctive treatment for hidradenitis suppurativa: its impact on disease control and quality of life. P0111, EADV Congress 2024, 25–28 September, Amsterdam, the Netherlands.
Copyright ©2024 Medicom Medical Publishers
Medical writing support provided by Dr Susanne Kammerer
Posted on
Previous Article
« Advanced BCC: histological subtype and time to complete response may predict tumour recurrence Next Article
Anti-KIT antibody: the next frontier in CSU treatment? »
« Advanced BCC: histological subtype and time to complete response may predict tumour recurrence Next Article
Anti-KIT antibody: the next frontier in CSU treatment? »
Table of Contents: EADV 2024
Featured articles
Delgocitinib cream outperforms oral alitretinoin in chronic hand eczema
Targeting IL-17A offers a promising treatment perspective in hidradenitis suppurativa
Online First
Delgocitinib cream outperforms oral alitretinoin in chronic hand eczema
Second-generation selective PDE-4 inhibitor shows promise in AD
HS: Bimekizumab shows sustained 2-year efficacy
JAK1 inhibitor shows promising long-term efficacy in PN
Deuruxolitinib significantly improves hair satisfaction in alopecia areata
Familial hidradenitis suppurativa associated with higher risk for metabolic disease
Targeting IL-17A offers a promising treatment perspective in hidradenitis suppurativa
Imsidolimab potential future therapeutic avenue for generalised pustular psoriasis
Prurigo nodularis: long-term treatment reduces relapse events
Atopic dermatitis early in life imposes a lifelong psychosocial burden
PsoBest registry: Biologics have become the first choice in moderate-to-severe psoriasis
Topical pan-JAK inhibitor mitigates inflammatory biomarkers in frontal fibrosing alopecia
Atopic hand eczema: similar treatment success for dupilumab and topical delgocitinib
IL-13 inhibitor shows safety and efficacy in AD over 3 years
Semaglutide: also beneficial for patients with HS?
Advanced BCC: histological subtype and time to complete response may predict tumour recurrence
New targets identified for chronic wound healing
Related Articles
November 28, 2023
JAK1 inhibition: a promising forthcoming treatment option in vitiligo
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com